GenScript Biotech (01548) has issued an announcement regarding its associate company, Legend Biotech Corporation, whose shares are listed on the Nasdaq Global Select Market in the form of American Depositary Shares.
On November 4, 2026 (New York time), which fell after the Hong Kong trading session on the same date, Legend submitted a Form 6-K to the U.S. Securities and Exchange Commission.
Legend announced that at the 68th American Society of Hematology Annual Meeting, to be held in New Orleans, Louisiana, from December 12 to 15, 2026, it will present two oral presentations, two poster presentations, and one electronic publication on research into CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of multiple myeloma.
In addition to the CARVYKTI data, Legend will present a poster on its allogeneic gamma-delta CAR-T cell therapy LUCAR G39D, which targets both CD20 and CD19, for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.
Legend will also present a poster on LB2501, its first in vivo CD19/CD20 dual-target CAR-T therapy, which is currently being evaluated in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Comments